To approve the releasing of directors of
non-competition restrictions at 2022 AGM
Date of events
2022/06/14
To which item it meets
paragraph 21
Statement
1.Date of the shareholders' meeting resolution:2022/06/14
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
(1) Lin Feng Co., Ltd. Representative: Tang Ten-Chien
(2) Independent Director : Wang Chang-Sheng
3.Items of competitive conduct in which the officer is
permitted to engage:
Companies with similar business covered by company's target industries.
4.Period of permission to engage in the competitive conduct:
Within period of serving as director of Company.
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
(1)Voting Status:
For:46,491,422rights;99.67% of the total represented at the time
of voting.
Against:28,881rights;0.06% of the total represented at the time
of voting.
Abstained:125,018rights;0.27% of the total represented at the time
of voting.
Invalid:0rights;0.00% of the total represented at the time of voting.
(2)Proposal Approved Upon Voting Result:
The resolution was adopted by a majority of the shareholders presented at
the general meeting who represented two-thirds or more of the total number
of shares represented by the attending shareholders at 2022/06/14 AGM.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter "N/A" below):N/A
7.Company name of the mainland China enterprise and the
officer's position in the enterprise:N/A
8.Address of the mainland China enterprise:N/A
9.Operations of the mainland China enterprise:N/A
10.Impact on the company's finance and business:None
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:None
12.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Arich Enterprise Co. Ltd. published this content on 14 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2022 12:02:04 UTC.
Arich Enterprise Co., Ltd. is a Taiwan-based company principally engaged in the sales and marketing of pharmaceuticals, as well as the provision of the related logistics services. The Company is principally engaged in the sale and marketing of prescription drugs for gynaecology, obstetrics, urinary, derma and ophthalmology use; guideline drugs for hair breeding, intestines and stomach and smoking quit, as well as health consumer goods for oral health, daily consuming and beauty care, among others. The Company also provides distribution and logistics services for prescription drugs, guideline drugs, restriction drugs, cold chain drugs, clinical trial drugs and healthcare products, among others. The Company operates its business mainly within domestic market.
ARICH ENTERPRISE CO., LTD. 
